Differences

This shows you the differences between two versions of the page.

--- home:mp [06.11.2018] – [Background and scientific rationale for the therapy] sallieq
+++ home:mp [03.12.2019] – [Endpoints of the Protocol] sallieq
@@ Line 30: / Line 30: @@
 <relatedarticles>
   * [[home:physicians:vitamin_d_leaflet|Testing your vitamin D metabolites]]
-  * [[home:protocol#science_behind_marshall_pathogenesis|Science behind Marshall Pathogenesis]]
+  * [[home:pathogenesis|Science behind Marshall Pathogenesis]]
   * [[home:protocol#science_behind_marshall_protocol|Science behind Marshall Protocol]]
   * [[home:mp:stages|Stages of illness and recovery]]
 </article>
@@ Line 237: / Line 237: @@
 {{section>:home:patients:mp_duration#after_completion_of_the_marshall_protocol&noheader}}
+==== Data ====
+[[home:patients:cohort_statistics#later_information_2013|Success rates for various Dx, compiled in 2013]]
 ===== Stopping the Protocol =====
@@ Line 248: / Line 252: @@
 Olmesartan will need to be [[home:mp:break:olmesartan#stopping_olmesartan|weaned very gradually]]. Note that the immune response may remain activated for a period of time even after discontinuing olmesartan. Patients who stop olmesartan are terminating their recovery.
+{{tag>MP summary}}
 ===== Notes and comments =====

home/mp.txt · Last modified: 09.14.2022 by 127.0.0.1